Sort
10,766 grants matching “checkpoint inhibitor”
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2021 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2016 · CA
Role of RON kinase in anti-tumor immune responses
$348,844Alana L Welm · University Of Utah · R01 · FY2020 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$348,835Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2021 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$348,832Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2020 · CA
Protein Kinase Signaling and Cell Cycle Control
$348,794Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2010 · ES
Optimizing systemic immunotherapy for personalized brain metastasis treatment
$348,747Michael Lim · Stanford University · U54 · FY2025 · CA
The CD93 pathway and melanoma therapy
$348,592Yuwen Zhu · University Of Colorado Denver · R01 · FY2023 · CA
MDC1: central regulator of estrogen receptor function and therapy response in lobular carcinoma
$348,592Matthew J Sikora · University Of Colorado Denver · R01 · FY2023 · CA
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
$348,426Fiona Simpkins · Johns Hopkins University · P50 · FY2019 · CA
A novel approach for the selective inhibition of HIF-2a in kidney cancer
$348,203Mei Yee Koh · University Of Utah · R01 · FY2017 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$348,182Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA
Mre11/Rad50 Structural Biology for DNA Damage Responses
$348,128John A Tainer · Scripps Research Institute, The · R01 · FY2007 · CA
DNA damage signaling to immune checkpoints
$347,953Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM
$347,923Amy Beth Heimberger · Northwestern University At Chicago · P50 · FY2025 · CA
Identification of Druggable Targets to Complement Melanoma Therapy
$347,918Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy
$347,829Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2024 · CA
Identification of Druggable Targets to Complement Melanoma Therapy
$347,768Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R01 · FY2020 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2018 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Novel NEK2 signaling pathways in myeloma progression
$347,700Fenghuang Zhan · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses
$347,558Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · CA
Vista, A Novel Checkpoint that Suppresses Anti-Tumor T Cell Responses
$347,558Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · CA